Objective—To compare use of doxorubicin, surgery,
and radiation versus surgery and radiation alone for
treatment of cats with vaccine-associated sarcoma.
Animals—25 cats with vaccine-associated sarcomas.
Procedure—Time to first recurrence and survival
time were compared between the 2 treatment
groups. The number of surgeries (1 or > 1) were compared
with respect to time to first recurrence and survival
Results—Median time to first recurrence was 661
days for the group that received doxorubicin, surgery,
and radiation. Median time to first recurrence has not
yet been attained for the group treated with surgery
and radiation alone. Median survival time was 674
days for the group treated with doxorubicin, surgery,
and radiation and 842 days for the group treated with
surgery and radiation alone. For time to first recurrence
and survival time, significant differences were
not detected between cats that had 1 surgery and
those that had > 1 surgery.
Conclusions and Clinical Relevance—Significant
differences between the 2 treatment groups were not
detected. The efficacy of doxorubicin in the treatment
of vaccine-associated sarcomas is uncertain. (J Am
Vet Med Assoc 2001;218:547–550)
Objective—To determine outcome for dogs with
grade-II mast cell tumors treated with surgery alone.
Procedures—Medical records were examined, and
signalment; location and size of tumor; staging status;
dates of local recurrence, metastasis, death, or last
follow-up examination; status of surgical margins; previous
surgery; postoperative complications; and
cause of death were recorded. Follow-up information
was obtained via reexamination or telephone conversations
with owners or referring veterinarians.
Univariate analysis was performed to identify prognostic
Results—60 tumors in 55 dogs were included.
Median follow-up time was 540 days. Three (5%)
mast cell tumors recurred locally; median time to local
recurrence was 62 days. Six (11%) dogs developed
another mast cell tumor at a different cutaneous location;
median time to a different location was 240 days.
Three (5%) dogs developed metastases; median time
to metastasis was 158 days. Fourteen dogs died; 3
deaths were related to mast cell tumor, and 7 were
unrelated. The relationship with mast cell tumor was
not known for 4. Median survival times were 151,
841, and 827 days, respectively, for these 3 groups.
Forty-six (84%) dogs were free of mast cell tumors
during the study period. A reliable prognostic factor
could not be identified.
Conclusions and Clinical Relevance—Results suggest
that additional local treatment may not be required
after complete excision of grade-II mast cell tumors
and that most dogs do not require systemic treatment.
(J Am Vet Med Assoc 2001;218:1120–1123)